False Hope and Deadly Consequences
Just when it seemed that the validity of science was gaining credibility among the masses the story of Aducanumab (Aduhelm) shows that profit still rules. Aducanumab is a drug that claims to slow the progression of Alzheimer’s Disease.
The Federal Drug Administration (FDA) approved the drug in June despite the fact that an advisory committee of experts outside of the FDA, as well as many Alzheimer’s specialists, said that that it was not clear if the drug provided benefit to patients. They noted that the drug presented a high level of risk because of serious side effects.
